Kindred At Home | |
1230 Northwood Center Ct, Suite C, Coeur D'alene, Idaho 83814 | |
(208) 667-5470 | |
Name | Kindred At Home |
---|---|
Location | 1230 Northwood Center Ct, Suite C, Coeur D'alene, Idaho |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 137112 |
Ownership Type | Proprietary |
Service Area Zip Codes | 83801, 83803, 83804, 83810, 83814, 83815, 83833, 83835, 83837, 83839, 83842, 83850, 83851, 83854, 83858, 83860, 83869, 83870, 83876, 83877 |
NPI Number | 1639109762 |
Organization Name | CENTERWELL CERTIFIED HEALTHCARE CORP. |
Doing Business As | CENTERWELL HOME HEALTH |
Address | 1230 W Northwood Center Ct, Suite C, Coeur D Alene, ID 83814 |
Phone Number | 208-667-5470 |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.
SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.
Can pyruvate, the end product of glycolysis, help improve cardiovascular function in children who have cardiopulmonary bypass surgery and suffer from low cardiac output syndrome? This question is one that Rafael Jaimes, Ph.D., a staff scientist at Children's National Heart Institute, a division of Children's National Health System, is studying, thanks to a two-year grant from the American Heart Association.
› Verified 3 days ago
Quality Rating: |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.
SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.
Can pyruvate, the end product of glycolysis, help improve cardiovascular function in children who have cardiopulmonary bypass surgery and suffer from low cardiac output syndrome? This question is one that Rafael Jaimes, Ph.D., a staff scientist at Children's National Heart Institute, a division of Children's National Health System, is studying, thanks to a two-year grant from the American Heart Association.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 99.1 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 99.9 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 99.3 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 85.6 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 83.9 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 93 | 96.4 |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.
SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.
Can pyruvate, the end product of glycolysis, help improve cardiovascular function in children who have cardiopulmonary bypass surgery and suffer from low cardiac output syndrome? This question is one that Rafael Jaimes, Ph.D., a staff scientist at Children's National Heart Institute, a division of Children's National Health System, is studying, thanks to a two-year grant from the American Heart Association.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 80.4 | 79.6 |
How often patients got better at getting in and out of bed | 81.5 | 81.1 |
How often patients got better at bathing | 81.6 | 82.3 |
How often patients’ breathing improved | 86.8 | 82.8 |
How often patients’ wounds improved or healed after an operation | 97 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 75.6 | 75 |
How often home health patients had to be admitted to the hospital | 13.5 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 16.8 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 75.9 | 94 |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.
SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.
Can pyruvate, the end product of glycolysis, help improve cardiovascular function in children who have cardiopulmonary bypass surgery and suffer from low cardiac output syndrome? This question is one that Rafael Jaimes, Ph.D., a staff scientist at Children's National Heart Institute, a division of Children's National Health System, is studying, thanks to a two-year grant from the American Heart Association.
› Verified 3 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.
SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.
Can pyruvate, the end product of glycolysis, help improve cardiovascular function in children who have cardiopulmonary bypass surgery and suffer from low cardiac output syndrome? This question is one that Rafael Jaimes, Ph.D., a staff scientist at Children's National Heart Institute, a division of Children's National Health System, is studying, thanks to a two-year grant from the American Heart Association.
› Verified 3 days ago
The patient survey data of Kindred At Home is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
Percent of patients who reported that their home health team communicated well with them | 89 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 80 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 89 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 86 | 78 |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.
SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.
Can pyruvate, the end product of glycolysis, help improve cardiovascular function in children who have cardiopulmonary bypass surgery and suffer from low cardiac output syndrome? This question is one that Rafael Jaimes, Ph.D., a staff scientist at Children's National Heart Institute, a division of Children's National Health System, is studying, thanks to a two-year grant from the American Heart Association.
› Verified 3 days ago